All News

Guselkumab a Hit in Phase III for PsA

d RheumNow

The monoclonal antibody guselkumab (Tremfya), which binds the interleukin (IL)-23 p19 subunit, was effective for psoriatic arthritis in two large clinical trials, providing comprehensive benefits for this heterogeneous disorder, investigators reported in The Lancet.

Read Article
knee.surg2_.jpg (keep)

Low Risk with Immunosuppression at Surgery

d Jack Cush, MD

The Annals of Rheumatic Disease reports that rheumatoid arthritis patients on biologic therapies do not have a greater risk of postoperative infection after hip fracture, abdominopelvic or cardiac surgery compared (compared with those on methotrexate alone) and that glucocorticoids were associated with a dose-dependent increase risk for postoperative infections.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – The Beginning of Something Else (4.10.20)

d Jack Cush, MD

Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com

Read Article
antibody (Keep)

Coagulopathy and Antiphospholipid Antibodies with Covid-19

d Jack Cush, MD

The New England Journal of Medicine has featured a report of three COVID infected patients, who developed peripheral and central infarcts with a antiphospholipid antibodies. 

Read Article
TNR.Safety_1.jpg

TNR - Grand Rounds: Safety of Biologics & New Agents

d Jack Cush, MD

On Tuesday, April 7th, RheumNow hosted its first Tuesday Nite Rheumatology webinar - kicking off a two-month series of Rheumatology Grand Rounds lectures.  The first session featured Jack Cush, MD (UT Southwestern) who lectured on "The Safety of Biologics and Newer Agents".

Read Article
mask.cough_.URI_.jpg

Incubation Period for COVID-19

d Jack Cush, MD

The incubation period for coronavirus disease 2019 (COVID-19) has important implications for surveillance and control activities. The Annals of Internal Medicine reports a pooled analysis of confirmed COVID-19 cases January 4, 2020 and February 24, 2020.

Read Article
kneepain3.jpg (keep)

Tanezumab: A Win as Last-Ditch Osteoarthritis Tx

d RheumNow

A phase III study of the nerve growth factor and monoclonal antibody tanezumab showed positive results in a refractory patient population with knee or hip osteoarthritis (OA) -- good enough that this agent may finally be approved after a long and rocky development road.

Read Article
HIV.virus_.jpg

COVID-19 Susceptibility: Why Do Some Become So Ill?

d RheumNow

The differential susceptibility to COVID-19 infection is attributable to socioeconomic factors and genetic differences, that together with environmental factors, human-virus interactions, gender, perhaps blood type, and age-related senescence determine the immune response and the likelihood of developing disease.

Read Article
Check out the RheumNow Podcast – The Beginning of Something Else (4.10.20); COVID & other organs, who's, latest #s,NICE guidelines for Rheum Pts - watch it on the website>> https://t.co/5INsHsMHvC or listen to the podcast on iTunes or SoundCloud>> https://t.co/8anP9uWJSQ

Links:

Dr. John Cush RheumNow ( View Tweet)

A retrospective case-control study shows that rheumatoid arthritis #RA patients have a significantly lower risk of dementia (OR 0.71,CI 0.52–0.98); even moreso with MTX Rx >4 yrs (OR 0.37). Sulfasalazine did not change the odds of getting dementia https://t.co/E679IT6aS7

Links:

Dr. John Cush RheumNow ( View Tweet)

“Try your best to make goodness attractive. That’s one of the toughest assignments you’ll ever be given.” - Mr Rogers

Dr. John Cush RheumNow ( View Tweet)

COVID-19: GI involvment does occur. Diarrhea in 3-24%, Nausea 10-18%, vomiting <4% and increased LFTs in up to one-third; and 28% of those with GI symptoms may not have respiratory symptoms. Virus has been found in stool samples. https://t.co/pErYDwuodT

Links:

Dr. John Cush RheumNow ( View Tweet)

"I hope you’re proud of yourself for the times you’ve said ‘yes,’ when all it meant was extra work for you and was seemingly helpful only to someone else" - Mr. Rogers

Dr. John Cush RheumNow ( View Tweet)

(1) We are delighted to announce that Kenneth Saag, MD MSc @KenSaag will serve as our next #UABRheumatology Division Director effective July 1st 2020 @uabmedicine @UABSOM @UABNews @UAB_NRTC @UABPulmonary @UABCardiology @UABGIM @uabSOPH @ONealCancerUAB @sethlandefeld @DrVickersUAB https://t.co/PMjhpWIptp
UAB Clinical Immunology and Rheumatology UABRheum ( View Tweet)
Wow! Further support for #PhysicalTherapy in knee #osteoarthritis, with this RCT demonstrating benefit over i.a. glucocorticoid injection. Congrats to @danrhon. @OARSInews @ACRheum https://t.co/2gsmqo9CM1 https://t.co/kXjus3pBlU

Links:

Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
Acute necrotizing encephalopathy a rare complication of COVID-19. Damage either from viral damage or cytokine storm, Symmetric, multifocal lesions @brain stem, cerebral white matter, cerebellum, thalamus w/ internal hemorrhage https://t.co/cWs1rsgzrO https://t.co/jura3IzkNI

Links:

Dr. John Cush RheumNow ( View Tweet)

"Often when you think you're at the end of something, you're at the beginning of something else." -Mr. Rogers

Dr. John Cush RheumNow ( View Tweet)

Children have a lower frequency of illness or death from COVID-19. Illness affects ~1% of those under 19yrs. In US, there have been no COVID ICU admissions or deaths among 4226 COVID patients under 19yrs (3/16/20). But kids may be carriers https://t.co/pyeTro5nJr

Links:

Dr. John Cush RheumNow ( View Tweet)

Reuters reports that the US death toll from the novel coronavirus topped 10,000 on Monday. The United States has the third-highest number of reported deaths from the disease in the world, exceeded only by Italy with 16,523 and Spain with 13,055. https://t.co/GitR3BdjK8

Links:

Dr. John Cush RheumNow ( View Tweet)

USA and Canada trends. Potential factors: Early intervention, Difference in population at risk, Pop Density, Citizen attitudes & leaders, Economic steps aiding citizen behaviour. How will this end? #COVID19 critical community size, #herdimmunity, #vaccine, #socialdistancing https://t.co/ImU3hFPkKg
Nigil Haroon MD, PhD NigilHaroon ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×